Endoscopic Retrograde Cholangiopancreatography
Conditions
Brief summary
* The investigators evaluated the role of allopurinol in prevention of post-ERCP pancreatitis. * 100 Egyptian patients who were candidates for ERCP were included and divided into two groups. Group 1 (study group) included 50 patients who received two doses of allopurinol 300 mg each, 15 hours and 3 hours before ERCP and Group 2 (control group) included 50 patients who did not receive allopurinol prophylaxis.
Detailed description
A diagnosis of procedure-related pancreatitis was based on an increased serum amylase level greater than three times the upper normal limits, associated with abdominal pain requiring analgesics and persisting for at least 24 hours after the procedure.
Interventions
DRUGAllopurinol
600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients who were going to be subjected to ERCP due to different causes
Exclusion criteria
* Patients with clinically evident acute pancreatitis or hyperamylesemia (≥150 IU/L) before the procedure. * Current or recent use of allopurinol (within the last 48 hours). * Hypersensitivity to allopurinol or hydro-soluble contrast solutions. * Current use of drugs with a known interaction with allopurinol, including cyclophosphamide, chlorpropamide, azathioprine, mercaptopurines, or probenecid. * NSAIDS intake within a week prior to assessment. * Previous endoscopic or surgical sphincterotomy. * Those with severe co-morbid conditions. * Female patients with a known or suspected pregnancy and/or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnosis of procedure-related pancreatitis | At least 24 hours after the ERCP |
Outcome results
None listed